Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Recruiting 14Active not recruiting 8Terminated 6Completed 3Not yet recruiting 2Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Liposarcoma 1Leiomyosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 37Gemcitabine 31Paclitaxel 27Cisplatin 27Carboplatin 27Capecitabine 27camrelizumab 24Nivolumab 23apatinib 22Oxaliplatin 21fludarabine 20Radiotherapy 20toripalimab 17Immunotherapy, Adoptive 17Drug Therapy 17pembrolizumab 16Docetaxel 16Dexamethasone 15Bevacizumab 15N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Injections 14tislelizumab 13Temozolomide 13Rituximab 13Cetuximab 13Irinotecan 12130-nm albumin-bound paclitaxel 11anlotinib 10Fluorouracil 10Trastuzumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × cemiplimab × Clear all
NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

OncoResponse, Inc.

Phase 1/2 Unknown
172 enrolled
DermatologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡